RecallWatchUSA

Home / Recalls / Drugs

Pacira Pharmaceuticals, Inc. recalls EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufa

Recalled December 11, 2019 · FDA recall D-0621-2020 · Pacira Pharmaceuticals

Hazard
Sub Potent Drug: Out of Specification (OOS) · FDA Class II
Units
910 20 mL vials
Sold at
Distributed Nationwide in the USA

Description

Sub Potent Drug: Out of Specification (OOS)

Product
EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20,
Manufacturer(s)
Pacira Pharmaceuticals, Inc.

Source: U.S. Food and Drug Administration. Official recall notice on fda.gov

Pacira Pharmaceuticals, Inc. recalls EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufa | RecallWatchUSA